{"id":4357,"date":"2019-03-01T21:38:40","date_gmt":"2019-03-01T20:38:40","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=4357"},"modified":"2026-03-16T21:04:50","modified_gmt":"2026-03-16T20:04:50","slug":"spinraza-nun-auch-in-china-zugelassen","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/spinraza-nun-auch-in-china-zugelassen\/","title":{"rendered":"Spinraza nun auch in China zugelassen"},"content":{"rendered":"\n<div class=\"wp-block-group alignwide has-subtle-background-color has-background is-layout-flow wp-block-group-is-layout-flow\">\n<p class=\"tw-text-wide\">\u00dcberseztes Zitat aus Pressemitteilung Biogen\u00ae:<\/p>\n\n\n\n<div class=\"wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-28f84493 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<blockquote class=\"wp-block-quote is-style-default is-layout-flow wp-block-quote-is-layout-flow\"><p>CAMBRIDGE, Massachusetts, 28. Februar 2019 (GLOBE NEWSWIRE) &#8211;&nbsp;<br><a rel=\"noreferrer noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=P1D42DFL4x1Bg8W5qogUPMXOrK9dzgLvlFVm4doB15kiFWolk_1UzyeMnha_H6HUjQEDsPBHYYvSyYxpf2xS6Q==\" target=\"_blank\">Biogen Inc.<\/a>&nbsp;(Nasdaq: BIIB) gab heute bekannt, dass SPINRAZA (Nusinersen) von der National Medical Products Association (NMPA) f\u00fcr die Behandlung von 5q-R\u00fcckenmark zugelassen wurde Muskelatrophie (SMA), wodurch die Pr\u00e4senz des Unternehmens in China erweitert wird.&nbsp;<br>Etwa 95 Prozent aller SMA-F\u00e4lle sind 5q-SMA-F\u00e4lle und damit die h\u00e4ufigste Form der Erkrankung.&nbsp;<br>SPINRAZA ist die erste in China zugelassene Behandlung von SMA, einer f\u00fchrenden genetischen Todesursache bei S\u00e4uglingen, die durch fortschreitende, schw\u00e4chende Muskelschw\u00e4che gekennzeichnet ist.<br><\/p><cite>Quelle: <a href=\"http:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-further-expands-presence-china-approval-spinrazar\">http:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-further-expands-presence-china-approval-spinrazar<\/a><\/cite><\/blockquote>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00dcberseztes Zitat aus Pressemitteilung Biogen\u00ae: CAMBRIDGE, Massachusetts, 28. Februar 2019 (GLOBE NEWSWIRE) &#8211;&nbsp;Biogen Inc.&nbsp;(Nasdaq: BIIB) gab heute bekannt, dass SPINRAZA (Nusinersen) von der National Medical Products Association (NMPA) f\u00fcr die Behandlung von 5q-R\u00fcckenmark zugelassen wurde Muskelatrophie (SMA), wodurch die Pr\u00e4senz des Unternehmens in China erweitert wird.&nbsp;Etwa 95 Prozent aller SMA-F\u00e4lle sind 5q-SMA-F\u00e4lle und damit die [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-4357","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=4357"}],"version-history":[{"count":1,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4357\/revisions"}],"predecessor-version":[{"id":39878,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4357\/revisions\/39878"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=4357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=4357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=4357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}